Navigation Links
New view of tumors' evolution
Date:3/13/2014

CAMBRIDGE, MA -- Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.

MIT cancer biologists at the Koch Institute for Integrative Cancer Research and geneticists from the Broad Institute have now performed the most comprehensive analysis to date of these changes in mice programmed to develop cancer. The team discovered mutations and other genetic disturbances that arise at certain stages of lung cancer development; the researchers were also able to identify tumor cells that broke free to spread to other organs.

The findings, described in the March 13 issue of Cell, suggest possible new targets for drugs for this aggressive form of cancer, known as small cell lung cancer. There are now very few targeted drugs for small cell lung cancer, a highly lethal form of lung cancer that is associated with tobacco use and is usually treated with chemotherapy drugs that have severe side effects.

"Right now, small cell lung cancer is really lagging behind with respect to therapies that target a specific mutation or genetic alteration in the tumors, because we don't know a lot about the drivers in these cancers," says David McFadden, a postdoc at MIT's Koch Institute for Integrative Cancer Research and one of the lead authors of the Cell paper.

Other lead authors of the paper are Koch Institute postdoc Thales Papagiannakopoulos and Broad Institute researchers Amaro Taylor-Weiner, Chip Stewart, and Scott Carter. Senior authors are Tyler Jacks, the David H. Koch Professor of Biology and director of the Koch Institute, and Gad Getz, director of cancer genome computational analysis at the Broad Institute and director of the bioinformatics program at Massachusetts General Hospital.

Tracking cancer progression

The research team studied a strain of mice that lacks two key tumor-suppressor genes, p53 and Rb. These mice develop small cell lung cancer, but scientists don't know exactly how the cancer progresses or which subsequent genetic alterations drive tumor growth.

In studies of human small cell lung cancer, it has been difficult to identify these driver mutations because potent carcinogens in cigarette smoke produce many mutations, most of which don't affect tumor growth. In the mouse model of the disease, fewer mutations arise because the mice are not exposed to cigarette smoke, making it easier to identify the key drivers.

Mice lacking p53 and Rb, the two most commonly mutated tumor suppressors in human small cell lung cancer, develop lung tumors that closely mimic the progression of human small cell lung cancer. These tumors are highly metastatic and usually spread to the lymph nodes near the lungs and then to the liver. The researchers isolated DNA from these tumors and analyzed the genetic alterations that occurred, including genetic mutations as well as changes in the number of copies of a gene or chromosome.

First, the researchers compared genetic alterations that appeared early and late in cancer development. They found that early on, tumors accumulate many extra copies of a gene called Mycl1, a known oncogene that helps cells ignore signals to stop growing. Because Mycl1 is mutated so early, it is found in nearly all of the tumor cells, making it a good drug target, McFadden says. There are currently no cancer treatments that specifically target Mycl1, but scientists are now working on drugs that target a closely related oncogene, MYC.

Later in tumor progression, the mouse cancer cells lose a gene called Pten, which has previously been found mutated in about 20 percent of small cell lung cancer patients. In normal cells, Pten regulates a critical signaling pathway called PI3K, which influences many aspects of cell growth and survival. When Pten is lost, the pathway becomes overactive, allowing tumor cells to grow very rapidly.

Drugs that target the PI3K pathway are now in the early stages of clinical testing in human patients.

Retracing metastasis

The researchers also compared the genomes of cells from the original lung tumors and from tumors that later appeared in other sites. This enabled them to retrace the tumor cells' paths and to determine which lung tumors were the sources of the metastases. They found that while multiple subsets of cells from the lung tumors could move to the lymph nodes, usually only a single subset from the lymph nodes spread to the liver.

"Our data really add to this emerging idea that metastatic spread is quite complicated, and that there may be different populations within a single cancer moving around to different sites, which may complicate treatments," McFadden says.

The researchers now hope to perform further genetic analysis to identify which mutations make certain cells more likely to metastasize. They also plan to try treating small cell lung tumors with chemotherapy drugs and observing the genetic changes that occur as cancer cells become resistant to treatment.


'/>"/>

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy
2. Going viral to target tumors
3. Robert Avery, D.O., M.S.C.E., studies innovations to improve vision in children with tumors
4. Study reveals mechanisms cancer cells use to establish metastatic brain tumors
5. Cancer vaccine could use immune system to fight tumors
6. Tumors light up with new, unique imaging system using scorpion venom protein and a laser
7. Targeting tumors: Ion beam accelerators take aim at cancer
8. DNA-built nanostructures safely target, image cancer tumors
9. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
10. Neuro-Oncology Pioneer Who Defined Standard of Care for Brain and Spinal Tumors Joins Capital Institute for Neurosciences
11. Study finds that carbon monoxide can help shrink tumors and amplify effectiveness of chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... further expand its existing adherence automation lines. The ATP® Mini and InspectRx® ... technology of TCG’s standard products, but at a size and price point that ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... services since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, ... all major international travel insurance products online, under their own brand. The online ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local ... and increased funds raised to support fine arts programs in Chester County’s Elementary ... in Freed-Hardeman University’s Loyd Auditorium. , More than 850 people attended the ...
(Date:7/20/2017)... ... 2017 , ... Med Tech Solutions (MTS), a leading health care cloud computing ... Constellation Inc., a move that will help the company better serve its clients and ... acquisition is expected to help MTS expand its presence in the Midwest ...
(Date:7/20/2017)... , ... July 19, 2017 , ... A July 5th ... successful weight loss surgery patients who had received a body contouring procedure reported experiencing ... beauty clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/13/2017)... , July 13, 2017  New York City-based market research ... markets should be aware of.  From new products to new ... detailed in a recently completed study, Potential Pipeline Disruptors ... 1.  Age-Driven Growth - True ... been aware of the impact the growing population and, to ...
Breaking Medicine Technology: